On January 5, 2023 InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, reported that the Company will present the latest clinical data of FGFR inhibitor gunagratinib (ICP-192) for the treatment of cholangiocarcinoma at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Gastrointestinal (ASCO GI) Cancers Symposium on January 19-21, 2023, which will be held online and offline in San Francisco, U.S (Press release, InnoCare Pharma, JAN 5, 2023, View Source [SID1234625947]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The 2023 ASCO (Free ASCO Whitepaper) GI Cancers Symposium is an influential academic exchange event in the gastrointestinal cancer in the world, offering the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care.
Poster Presentation
Title: Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study
Abstract Number: 572
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Presentation Time: 12:00 PM -1:30 PM, Jan. 20, U.S. Time
Presenter: Professor Ye Guo